Today's Hours: 8:00am - 6:00pm

Search

Filter Applied Clear All

Did You Mean:

Search Results

  • Book
    Veronique Leblond, Steve Treon, Meletios Dimoploulos [e.g. Dimopoulos], editors.
    Summary: This book sheds new light on clinical, biological and therapeutic data on the rare disease Waldenström's Macroglobulinemia (WM) with the participation of widely-recognized experts, involved in this field. It represents the efforts of physicians, scientists and patients, all around the world, to better understand and cure this rare disease. Considerable advances in the diagnosis, treatment indications, response criteria, prognostic factors and treatment options have been made since Dr Jan Waldenström first reported this "new syndrome" 70 years ago. Particularly instrumental in advancing of our understanding of WM have been the eight international workshops devoted to this disease. New, exciting molecular data have recently been reported, allowing us to revisit the oncogenic events leading to WM B-cell proliferation and to use newly available compounds targeting oncogenic pathways.

    Contents:
    Preface: Tribute to J Waldenström
    Part I: Tumor Cells and microenvironment
    Waldenström Macroglobulinaemia: Pathological Features and Diagnostic Assessment
    Waldenström's Macroglobulinemia Immunophenotype
    Predispositions and Origins of Waldenstrom Macroglobulinemia: Implications from Genetic Analysis
    Cytogenetics in Waldenstr<öm Macroglobulinemia (WM)
    Genetic and Signaling Abnormalities in Waldenström's Macroglobulinemia
    Molecular Pathways in Growth and Survival: Epigenomics
    The Bone Marrow Microenvironment and Tumor Cells Interactions in Waldenström's Macroglobulinemia
    Waldenström's Macroglobulinaemia: Immunosurveillance and the Immune Micro-environment
    Part II: Epidemiology and Genetic Predisposition
    Epidemiology of Waldenström Macroglobulinemia
    Genetic Predisposition to Waldenström Macroglobulinemia
    Immunoglobulin Type M Monoclonal Gammopathy of Undetermined Significance (IgM-MGUS)
    Part III: Clinical Features
    Hyperviscosity Syndrome, Cold Agglutinin Hemolytic Anemia, and Cryoglobulinemia
    Neuropathy in Waldenström's Macroglobulinaemia
    IgM Amyloidosis
    The Bing-Neel Syndrome
    Unusual Manifestations of IgM Monoclonal Gammopathies
    Part IV: Laboratory Investigations
    Laboratory Investigations and Findings: Hematological Abnormalities, Biochemical Investigations, Free Light and Heavy Chains
    Part V: Response
    Response Assessment in Waldenström's Macroglobulinaemia
    Part VI: Prognostic Factors
    Risk Stratification in Waldenström Macroglobulinemia
    Part VII: Treatment Options and Recommendations
    Indications for Treatment of Waldenström's Macroglobulinemia
    Immunotherapy in Waldenström's Macroglobulinemia
    Immunomodulatory Agents and Proteasome Inhibitors in Waldenström's Macroglobulinemia
    Signal Inhibitors in Waldenström's Macroglobulinemia
    High-Dose Therapy and Haemopoietic Stem Cell Transplantation in Waldenström's Macroglobulinaemia
    Long-Term Toxicity of Therapy in Waldenström Macroglobulinemia
    Treatment Recommendations in Waldenström Macroglobulinemia.
    Digital Access Springer 2017